ABSTRACT
The aim of this study was to explore the analgesic effect of local application of compound lidocaine/prilocaine cream on cancer wounds during wound care in order to reduce the amount of morphine intake or completely replace the systemic morphine administration and optimize the protocol for cancer wound pain management. All patients were enrolled with a visual analog scale (VAS) pain score ≥4. Before wound care, 60 patients were randomly divided into 2 groups of 30 each: morphine group (10 mg tablet); topical 5% compound lidocaine cream group (0.2 g/cm2). VAS scores, heart rate, and Kolcaba comfort level were recorded for the two groups 10 min before and 10, 15, 20, and 25 min after wound care and data were analyzed statistically. The means for the pain score and heart rate of the topical lidocaine/prilocaine cream group were lower than those of the morphine group (P<0.01) and the Kolcaba comfort level was higher (P<0.01). Local dermal application of the compound lidocaine cream can be used as an alternative to the systemic morphine administration in cancer wound care for its safety and effectiveness. In addition, it can improve the patients' comfort and quality of life.
Subject(s)
Anesthetics, Combined/administration & dosage , Lidocaine, Prilocaine Drug Combination/administration & dosage , Neoplasms/complications , Pain Management/methods , Wounds and Injuries/drug therapy , Adult , Aged , Female , Humans , Male , Middle Aged , Pain Measurement , Quality of Life , Treatment Outcome , Wounds and Injuries/etiologyABSTRACT
The aim of this study was to explore the analgesic effect of local application of compound lidocaine/prilocaine cream on cancer wounds during wound care in order to reduce the amount of morphine intake or completely replace the systemic morphine administration and optimize the protocol for cancer wound pain management. All patients were enrolled with a visual analog scale (VAS) pain score ≥4. Before wound care, 60 patients were randomly divided into 2 groups of 30 each: morphine group (10 mg tablet); topical 5% compound lidocaine cream group (0.2 g/cm2). VAS scores, heart rate, and Kolcaba comfort level were recorded for the two groups 10 min before and 10, 15, 20, and 25 min after wound care and data were analyzed statistically. The means for the pain score and heart rate of the topical lidocaine/prilocaine cream group were lower than those of the morphine group (P<0.01) and the Kolcaba comfort level was higher (P<0.01). Local dermal application of the compound lidocaine cream can be used as an alternative to the systemic morphine administration in cancer wound care for its safety and effectiveness. In addition, it can improve the patients' comfort and quality of life.
Subject(s)
Humans , Male , Female , Adult , Middle Aged , Aged , Wounds and Injuries/drug therapy , Anesthetics, Combined/administration & dosage , Pain Management/methods , Lidocaine, Prilocaine Drug Combination/administration & dosage , Neoplasms/complications , Quality of Life , Wounds and Injuries/etiology , Pain Measurement , Treatment OutcomeABSTRACT
This study aims to investigate the correlation between allergic sensitization of atopic dermatitis (AD) patients and their serum interleukin (IL)-16 levels. AD patients, healthy volunteers, and patients with psoriasis (N = 80, 35, 20, respectively) were tested for serum IL-16 and total and specific IgE levels by enzyme-linked immunosorbent assay, along with eosinophil counts. Serum allergen-specific IgE levels were determined, and skin-prick testing conducted in a subgroup of 45 AD patients. Based on specific IgE levels, AD patients were categorized into non-sensitized group 1 and sensitized group 2. Furthermore, they were sorted as non-sensitized group A and sensitized group B based on skin-prick results. Next, the serum IL-16 and total IgE levels in these subgroups were determined. Compared to levels in healthy volunteers and psoriasis patients, the serum IL-16 levels in AD patients were significantly higher (P < 0.001). Additionally, total serum IgE levels were significantly correlated with serum IL-16 levels and eosinophil counts. However, no correlation was observed between serum IL-16 levels and eosinophil counts. The serum IL-16 and total IgE levels in group 2 were also significantly elevated (P < 0.001) in contrast to those in group 1. Although we did not observe any significant difference between serum IL-16 levels in groups A and B, the total serum IgE level in group B was significantly higher than that in group A (P < 0.001). Thus, allergic sensitivity in AD patients correlates with total serum IgE as well as serum IL-16; the correlation with IL-6 is weaker.
Subject(s)
Dermatitis, Atopic/blood , Interleukin-16/blood , Adolescent , Adult , Child , Enzyme-Linked Immunosorbent Assay , Eosinophils/cytology , Female , Humans , Immunoglobulin E/blood , Male , Middle Aged , Psoriasis/blood , Young AdultABSTRACT
The GAL4/UAS binary system has been widely used in Drosophila melanogaster for ectopic expression of transgenes in a tissue-specific manner. The GMR-GAL4 driver, which expresses the yeast transcription factor GAL4 under the control of glass multiple reporter (GMR) promoter elements, has been commonly utilized to express target transgenes, specifically in the developing eye. However, we have observed abnormal wing phenotypes; this is a result of the activity of critical wing developing genes, e.g., components of the Notch or Wg pathway, that are up- or down-regulated under the control of the GMR-GAL4 driver. X-gal staining confirmed that UAS-LacZ is expressed in third-instar larva wing imaginal discs, as well as in eye discs, when driven by the GMR-GAL4 driver. Furthermore, we found that GMR-GAL4 also drives UAS-LacZ expression in other tissues, such as brain, trachea, and leg discs. These results indicate that GMR-GAL4 has a broad expression profile, rather than the eye-specific pattern described previously, and that one should be careful when using it as a tool for targeted gene expression.
Subject(s)
Drosophila melanogaster/genetics , Gene Expression Profiling , Gene Expression Regulation, Developmental , Animals , Drosophila Proteins/genetics , Drosophila Proteins/metabolism , Drosophila melanogaster/growth & development , Eye/growth & development , Eye/metabolism , Genes, Reporter , Phenotype , Promoter Regions, Genetic/genetics , Receptors, Notch/genetics , Receptors, Notch/metabolism , Signal Transduction/genetics , Transcription Factors , Wings, Animal/growth & development , Wings, Animal/metabolism , Wnt1 Protein/genetics , Wnt1 Protein/metabolismABSTRACT
Camellia is an economically important ornamental plant that has many uses, such as in beverages, foods and medicines. We examined 15 Camellia cultivars in Wenzhou, China, using RAPD markers and measurements of three traits (petal color, flower diameter, blooming period). PCR amplification with 15 random primers produced 1935 bands, observed at 88 amplification loci; 77% of the amplified loci were polymorphic, with a mean of 4.5 polymorphic loci per primer. The similarity coefficient ranged from 0.5419 to 0.7933 among the 15 samples; the lowest value was between Manao (C. reticulata) and Feibai FR (C. japonica), and the largest value was between Chidan (C. japonica) and Yuanyang FG (C. japonica). Cluster analysis divided the 15 cultivars into two groups at the similarity coefficient of 0.65. A correlation was found between RAPD markers and petal color in the first group. No correlation was found between RAPD markers and the other traits (flower diameter, blooming period). This study provides information useful for the identification, classification, phylogenesis, and breeding of Camellia cultivars.